PDF factsheet
      Z

immune checkpoint inhibition in renal-cell carcinoma (advanced) for all type of patients, clinical trials results

nivolumab versus everolimus
Chekmate 025 (Motzer), 2015
NCT01668784
3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks
versus
10-mg everolimus tablet orally once daily
patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapyopen-label
nivolumab + ipilimumab versus sunitinib
CheckMate-214, 2017
NCT02231749
nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks
versus
sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment
intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinomaopen-label

  Options


in first

in second

  Filter